DOCSLIB.ORG

Johnson & Johnson 2016 Annual Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Johnson & Johnson 2016 Annual Report ANNUAL REPORT 2016 MARCH 2017 TO OUR SHAREHOLDERS ALEX GORSKY Chairman and Chief Executive Officer I’ve worked in the health care industry for Rather, true innovations are the result of WE ARE UNITED nearly 30 years. It’s been both an honor and collaboration. And that collaboration is AND INSPIRED a privilege to work for Johnson & Johnson, driven by a diversity of ideas, individuals BY OUR CREDO, a company that touches the lives of over and disciplines – working together toward WHICH RINGS a billion people every day, around the a common goal. AS TRUE TODAY world. As I look at today’s health care AS IT DID WHEN landscape, it’s incredibly clear that the Today, more than ever, the world needs IT WAS WRITTEN pace of change has never been greater, leaders who are committed to working MORE THAN 70 or frankly, more exciting. together to help bring improved health YEARS AGO. and wellness to every person in every Today’s rapid change brings both corner of the globe. As the world’s largest opportunities and risks for any company and most broadly based health care in health care, and we are prepared company, we are uniquely positioned to help to address both. There are significant transform global health care; to shine a light challenges to overcome, but the tools, the on the most important issues we are facing; insights, the technologies, the innovations to collaborate across boundaries and – both evolutions and revolutions – all borders; to uncover scientific insights and combine to make today one of the most ideas; and to dedicate resources towards promising times for human health and for creating tomorrow’s breakthroughs. Johnson & Johnson. We are united and inspired by Our Credo, For over 130 years, our company has been which rings as true today as it did when inventing the future of health care. From it was written more than 70 years ago. the beginning, we learned that innovation It reminds us that our first responsibility is seldom the product of a solitary genius. is to our customers and patients, and it CHAIRMAN’S LETTER • I compels us to deliver on our responsibilities world’s largest and most comprehensive to our employees, our communities, our health care company, no one is better environment, and our shareholders. positioned than Johnson & Johnson to lead this important work. With that strong foundation, we will continue to use our breadth to In addition to our commitment to advance comprehensively advance human health; health comprehensively, we also employ invest for enduring, long-term impact; disciplined portfolio management to position our businesses to deliver strong, ensure we are focused on solving the consistent and sustainable results; most important medical and consumer hold ourselves accountable for our health needs, investing in promising future responsibilities; and put people first. growth areas and that all of our businesses continue meeting our expectations. During ADVANCING HUMAN HEALTH 2016, we completed 14 acquisitions or WE HAVE TO We believe having a business that significant licensing deals, as well as eight PUT THE PATIENT is broadly based in health care has divestitures, positioning us for continued IN THE CENTER been and will continue to be a major profitable growth. AND REWARD factor in our success. It has allowed us INNOVATIONS to deliver strong and consistent growth, Our acquisition of Abbott Medical Optics, THAT DRIVE as well as return significant value to which closed in early 2017, is an excellent BETTER our shareholders, throughout various example of our flexibility to invest in areas OUTCOMES & economic cycles. of opportunity across the spectrum of LONG-TERM health care. Our consumer expertise, VALUE. Our company’s structure also allows us particularly in the vision care space, to interconnect our breadth and depth to combined with our medical device drive innovation, and to take advantage of expertise, made this opportunity uniquely growth opportunities wherever they may complementary to our portfolio. We be across the dynamic health industry. This are excited about adding a strong and is particularly important as the industry differentiated surgical ophthalmic offering continues to evolve, and as the political – particularly in cataract surgery – to our environment poses new challenges and vision care business. That, coupled with opportunities. In 2016, this was incredibly our world-leading ACUVUE® contact lens clear in the emerging area of HealthTech. business, will help us become a broad- The potential for the intersection of based leader in vision care. This transaction technology and health care to completely is an excellent example of our approach change and disrupt the existing health care to acquisitions – it was the right deal, ecosystem has never been more imminent. at the right time and at the right price, This new HealthTech space is becoming to drive growth and create value for our integral to everything that we do, and as the shareholders. II • CHAIRMAN’S LETTER Our broad base across health care and INVESTING FOR LONG-TERM strong global footprint also gives us unique GROWTH insight and opportunities to work with In the same way that we are driven to OUR BROAD governments and health care systems save and improve lives, we have a very BASE IN HUMAN around the world to influence investments clear perspective on the imperatives for HEALTH CARE in health. The volatility that we see in our financial performance: our objective EXTENDS emerging markets, and the health care cost is for Johnson & Johnson to grow sales OUR REACH, challenges that exist in both developed organically at a faster rate than the market, CAPABILITIES and emerging markets, clearly demonstrate and grow our earnings faster than sales; AND STRATEGIC the importance of advocating for improved an objective we met in 2016. ADVANTAGES access to quality health care, as well as FOR PATIENTS, rewards for innovations that drive better Additionally, our focus on having a strong PROVIDERS AND outcomes and long-term value. We will cash flow ensures we are able to make CONSUMERS continue to be a leading voice in these the appropriate investments in our AROUND THE discussions, advocating for solutions that business, and then capitalize on the right WORLD. are in the best interests of the health and opportunities to create greater long-term wellness of patients and consumers. value for our shareholders. We start by funding our internal growth initiatives, including our investments in research and development. $ In 2016, our R&D After funding our organic growth, investments totaled 9.1B $9.1 billion. we have a strategic capital allocation framework that outlines how we will use our remaining free cash flow. $ In 2016, our free Our first priority is delivering a competitive B cash flow was dividend to our shareholders, which we 15.5 $15.5 billion*. have increased for 54 consecutive years. In 2016, we paid $ B $8.6 billion in 8.6 dividends. After meeting our dividend goals, we target value creating acquisitions. $ In 2016, we invested B approximately $5 billion Finally, we consider other prudent ways to 5 in acquisitions and major return value to shareholders, such as licensing deals. share repurchase programs. $ In 2016, we completed B two-thirds of our 10 $10 billion share repurchase program. CHAIRMAN’S LETTER • III Our total shareholder return for 2016 For 2017, we expect our key catalysts for was a strong 15.3%, significantly exceeding growth will include: our competitor composite, as well as • Continued strong performance of our exceeding most major indices, including in-line products – increasing penetration the S&P 500. This is not only true for 2016, in markets such as anti-coagulants, but I’m proud to say it’s also the case over psoriasis, and long-acting anti-psychotics the last three, five, ten and twenty year • Capitalizing on the early launch success periods. Historically, approximately 70 from key products such as DARZALEX®, percent of our free cash flow deployed IMBRUVICA®, and STELARA® for over the last 10 years has been returned Crohn’s Disease to shareholders in the form of dividends or • Anticipated regulatory approval for two share repurchases. new immunology products, guselkumab ALL THREE OF and sirukumab, each with greater than OUR BUSINESS Our strong record of total shareholder $1 billion in sales potential SECTORS returns is the result of our approach to ARE WELL- managing for the long term, our relentless Further, we will continue to vigorously POSITIONED drive for innovation, our disciplined portfolio defend our patents on REMICADE®, while TO MEET THE management and our capital allocation remaining competitive against at-risk CHANGING strategy – all of which are regularly biosimilar entries, given the product’s long NEEDS OF discussed as part of our ongoing strategic track record of efficacy and safety. PATIENTS AND planning with our Board of Directors. CONSUMERS We are confident in our robust DRIVING STRONG, CONSISTENT, Pharmaceutical pipeline and will continue SUSTAINABLE RESULTS working toward our goal of filing 10 new As the health care landscape continues to products by 2019, each with at least $1 evolve, all three of our business sectors are billion in potential sales, as well as filing an well-positioned to meet the changing needs additional 40 line extensions by 2019, 10 of patients and consumers. In terms of our of which have more than $500 million in financial performance, we expect each potential sales. business segment to grow and contribute to our sales and income growth in 2017. In addition, in January 2017 we announced a definitive agreement to acquire Actelion PHARMACEUTICALS Ltd. for approximately $30 billion. The In our Pharmaceuticals business, our transaction is expected to accelerate priority is to drive continued growth while our near- and long-term revenue and delivering on our near-term pipeline.
Load more

Recommended publications
  • From the Academy
    FROM THE ACADEMY Joint American Academy of DermatologyeNational Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy Craig A. Elmets, MD (Co-Chair),a HenryW.Lim,MD,b Benjamin Stoff, MD, MA,c Cody Connor, MD,a Kelly M. Cordoro, MD,d Mark Lebwohl, MD,e AprilW.Armstrong,MD,MPH,f Dawn M. R. Davis, MD,g Boni E. Elewski, MD,a Joel M. Gelfand, MD, MSCE,h Kenneth B. Gordon, MD,i AliceB.Gottlieb,MD,PhD,j Daniel H. Kaplan, MD, PhD,k Arthur Kavanaugh, MD,l Matthew Kiselica, BA/BS,m Dario Kivelevitch, MD,n Neil J. Korman, MD, PhD,o Daniela Kroshinsky, MD, MPH,p Craig L. Leonardi, MD,q Jason Lichten, MD,m NehalN.Mehta,MD,MSCE,r Amy S. Paller, MD,s Sylvia L. Parra, MD,t Arun L. Pathy, MD,u Elizabeth A. Farley Prater, MD,v Reena N. Rupani, MD,e Michael Siegel, PhD,m BruceE.Strober,MD,PhD,w,x Emily B. Wong, MD,y Jashin J. Wu, MD,z Vidhya Hariharan, PhD,aa and Alan Menter, MD (Co-Chair)n Birmingham, Alabama; Detroit, Michigan; Atlanta, Georgia; San Francisco, Los Angeles, San Diego, and Irvine, California; New York, New York; Rochester, Minnesota; Philadelphia and Pittsburgh, Pennsylva- nia; Milwaukee, Wisconsin; Portland, Oregon; Dallas and San Antonio, Texas; Cleveland, Ohio; Boston, Massachusetts; St. Louis, Missouri; Bethesda, Maryland; Chicago and Rosemont, Illinois; Sumter, South Carolina; Centennial, Colorado; Oklahoma City, Oklahoma; Farmington, Connecticut; and Waterloo, Ontario, Canada Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 3.2% of the world’s population.
    [Show full text]
  • Resource #350932
    −This Clinical Resource gives subscribers additional insight related to the Recommendations published in− September 2019 ~ Resource #350932 Anticipated Availability of First-Time Generics ―To help explain the benefits of generic drugs to your patients, the FDA has patient education materials available at https://www.fda.gov/drugs/generic-drugs/patient-education ― Branda Generic Name Generic Manufacturer(s)b,1 Anticipated Availabilityc (Manufacturer) Acanya Benzoyl peroxide 2.5%/ Teva Generic now available (Valeant) Clindamycin phosphate 1.2% Cuprimine Penicillamine capsule Amerigen, Teva Generic now available (Bausch Health) Delzicol Mesalamine delayed-release Teva Generic now available (Warner Chilcott) capsule Diclegis Doxylamine/Pyridoxine Teva Generic now available (Duchesnay) Exjade Deferasirox tablets for oral Teva Generic now available (Novartis) suspension Fareston Toremifene Rising (EirGen Pharma Limited) Generic now available (Kyowa Kirin) Faslodex Fulvestrant Sandoz Generic now available (AstraZeneca) Firazyr Icatibant Teva Generic now available (Shire Orphan Therapies) Gablofen Baclofen 1 mg/mL single dose Mylan Institutional Generic now available (Piramal) vial Hemabate Carboprost tromethamine Dr. Reddy’s Generic now available (Pharmacia & Upjohn) Letairis Ambrisentan Cipla, Mylan, Par, Sigmapharm, Sun, Teva, Generic now available (Gilead) Zydus Lexiva Fosamprenavir Mylan Generic now available (Viv) More. Copyright © 2019 by Therapeutic Research Center 3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249 pharmacist.therapeuticresearch.com ~ prescriber.therapeuticresearch.com ~ pharmacytech.therapeuticresearch.com ~ nursesletter.therapeuticresearch.com (Clinical Resource #350932: Page 2 of 24) Branda Generic Name Generic Manufacturer(s)b,1 Anticipated Availabilityc (Manufacturer) Lotemax Loteprednol ophthalmic Hi-tech Generic now available (Bausch & Lomb) suspension Lyrica Pregabalin capsule Alembic, Amneal, Ascend (Alkem), Cipla Generic now available (PF Prism CV) (InvaGen), Dr.
    [Show full text]
  • Responding to Mylan's Inadequate Tender Offer
    Responding To Mylan’s Inadequate Tender Offer: Perrigo’s Board Recommends That You Reject the Offer and Do Not Tender September 2015 Important Information Forward Looking Statements Certain statements in this presentation are forward-looking statements. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control, including future actions that may be taken by Mylan in furtherance of its unsolicited offer. These and other important factors, including those discussed under “Risk Factors” in the Perrigo Company’s Form 10-K for the year ended June 27, 2015, as well as the Company’s subsequent filings with the Securities and Exchange
    [Show full text]
  • Gilead Sciences, Inc. November 13, 2016
    Student Investment Management Gilead Sciences, Inc. November 13, 2016 Gilead Sciences, Inc. NASDAQ: GILD BUY $92.00 The Fisher College of Business Student Investment Management Program is initiating coverage on Gilead Sciences with a BUY rating. Our target price is $92.00. Our implied P/E for 2016E is 7.9x versus consensus 6.5x. Our 2017 and 2018 estimates are 8.8x and 9.5x, respectively. Company overview Gilead Sciences, Inc. is a research-based biopharmaceutical Fund Manager company that discovers, develops and commercializes innovative Royce West, CFA medicines in areas of unmet medical need. Gilead strives to 614-227-2948 transform and simplify care for people with life-threatening illnesses [email protected] around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver Analyst diseases, cancer, inflammatory and respiratory diseases, and Andrew Jasen cardiovascular conditions. 301-300-0702 [email protected] 12-Month trading performance 10.0% S&P Current share price: $72.64 7.0% 52 wk range: $71.76 - $108.13 0.0% S5HLTH Market cap: $99.9bn 1.4% P/E: 6.8x (10.0%) XBI (3.0%) Diluted shares out.: 1.3bn Last dividend (9/4/2016): $0.47 (20.0%) GILD Dividend yield: 2.4% (25.5%) Beta: 0.94 (30.0%) EV/EBITDA: 4.8x EV/Sales: 3.1x (40.0%) Nov-15 Jan-16 Mar-16 May-16 Jul-16 Sep-16 Nov-16 Investment thesis We are placing a BUY rating on GILD with a price target of $92.00, a 20.4% upside to the current trading price.
    [Show full text]
  • 2015 Annual Report
    ANNUAL REPORT 2015 MARCH 2016 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer This year at Johnson & Johnson, we are proud this aligned with our values. Our Board of WRITTEN OVER to celebrate 130 years of helping people Directors engages in a formal review of 70 YEARS AGO, everywhere live longer, healthier and happier our strategic plans, and provides regular OUR CREDO lives. As I reflect on our heritage and consider guidance to ensure our strategy will continue UNITES & our future, I am optimistic and confident in the creating better outcomes for the patients INSPIRES THE long-term potential for our business. and customers we serve, while also creating EMPLOYEES long-term value for our shareholders. OF JOHNSON We manage our business using a strategic & JOHNSON. framework that begins with Our Credo. Written OUR STRATEGIES ARE BASED ON over 70 years ago, it unites and inspires the OUR BROAD AND DEEP KNOWLEDGE employees of Johnson & Johnson. It reminds OF THE HEALTH CARE LANDSCAPE us that our first responsibility is to the patients, IN WHICH WE OPERATE. customers and health care professionals who For 130 years, our company has been use our products, and it compels us to deliver driving breakthrough innovation in health on our responsibilities to our employees, care – from revolutionizing wound care in communities and shareholders. the 1880s to developing cures, vaccines and treatments for some of today’s most Our strategic framework positions us well pressing diseases in the world. We are acutely to continue our leadership in the markets in aware of the need to evaluate our business which we compete through a set of strategic against the changing health care environment principles: we are broadly based in human and to challenge ourselves based on the health care, our focus is on managing for the results we deliver.
    [Show full text]
  • Pfizer and Mylan Will Own 57% and 43% of the New Company (“Newco”), Respectively
    DEAL PROFILE PFIZER | MYLAN VALUES 57% 43% $12.0bn PFIZER SHARE OF NEWCO MYLAN SHARE OF NEWCO NEW DEBT RAISED Pfizer Inc. (NYSE:PFE) Pfizer Inc. (“Pfizer”) is a pharmaceutical company that develops, manufactures, and sells products in internal medicine, vaccines, oncology, inflammation & immunology, and rare diseases. Upjohn, a subsidiary of Pfizer, is composed of Pfizer’s oral solid generics and off-patent drugs franchise, such as Viagra, Lipitor, and Xanax. Upjohn has a strong focus in emerging markets, and is headquartered in Shanghai, China. TEV: $265.4bn LTM EBITDA: $22.5bn LTM Revenue: $55.7bn Mylan N.V. (NASDAQ:MYL) Mylan N.V. (“Mylan”) is a pharmaceutical company that develops, manufactures, and commercializes generic, branded-generic, brand-name, and over-the-counter products. The company focuses in the following therapeutic areas: cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women’s health. Mylan was founded in 1961 and is headquartered in Canonsburg, PA. TEV: $23.9bn LTM EBITDA: $3.5bn LTM Revenue: $11.3bn Bourne Partners provides strategic and financial advisory services to BOURNE clients throughout the business evolution life cycle. In order to provide PARTNERS the highest level of service, we routinely analyze relevant industry MARKET trends and transactions. These materials are available to our clients and partners and provide detailed insight into the pharma, pharma services, RESEARCH OTC, consumer health, and biotechnology sectors. On July 29, 2019, Pfizer announced the spin-off of its off-patent drug unit, Upjohn, in order to merge the unit with generic drug manufacturer, Mylan.
    [Show full text]
  • Amgen-Opinion-Jan-7-2021.Pdf
    IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELA WARE AMGEN INC. and AMGEN MANUFACTURING, LIMITED, Plaintiffs, v. Civil Action No. 20-0561-CFC HOSPIRA, INC. and PFIZER INC. Defendants. MEMORANDUM ORDER Having considered the merits of Defendants Hospira, Inc. and Pfizer Inc.' s Motion to Stay (D.I. 19) and the briefs filed by the parties in connection with that motion, it is HEREBY ORDERED that Defendants' motion to stay is GRANTED IN PART for the following reasons: 1. Plaintiffs Amgen Inc. and Amgen Manufacturing, Limited make and sell the biologic filgrastim under the brand name Neupogen®. Filgrastim, like many biologics, is a protein. Plaintiffs own two patents generally related to methods of purifying such proteins. These two patents are U.S. Patent Nos. 10,577,392 (the #392 patent), and 9,643,997 (the #997 patent). The #392 patent issued in March of 2020. 2. Defendants manufacture and sell a biosimilar version Neupogen® called Nivestym®. Nivestym® has been available since 2018 and is the third biosimilar version ofNeupogen® launched in the United States since Neupogen® became available almost thirty years ago. 3. Both the #392 patent and #997 patent have been asserted against the Defendants-albeit in different actions-for the manufacture ofNivestym®. The #392 patent has been asserted in this case (C.A. 20-0561 ), which was filed on April 24, 2020. The #997 patent has been asserted in the related case Amgen Inc. et al. v. Hospira, Inc. et al., No. 18-cv-1064-CFC-CJB (D. Del. 2018). That case is scheduled for a jury trial to begin on May 17, 2021.
    [Show full text]
  • Mylan Signs Agreement with Gilead to Enhance Access to Tenofovir Alafenamide (TAF)- Based HIV Treatments in Developing Countries
    December 1, 2014 Mylan Signs Agreement with Gilead to Enhance Access to Tenofovir Alafenamide (TAF)- based HIV Treatments in Developing Countries PITTSBURGH and HYDERABAD, India, Dec. 1, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences, Inc. under which Mylan has licensed the non-exclusive rights to manufacture and distribute Tenofovir Alafenamide (TAF) as both a single agent product and in combination with other drugs. Tenofovir Alafenamide (TAF) is an investigational antiretroviral drug for the treatment of HIV-1 infection. The license being granted to Mylan extends to 112 countries, which together account for more than 30 million people living with HIV, representing 84% of those infected globally.1 Mylan CEO Heather Bresch said, "Mylan's mission is to provide the world's 7 billion people access to high quality medicines and set new standards in health care. By working with partners like Gilead to help ensure access to innovative new products such as Tenofovir Alafenamide (TAF) in the countries hardest hit by this disease, we can help stem the tide of HIV/AIDS around the world." As part of the licensing agreement, on U.S. Food and Drug Administration (FDA) approval, Mylan will receive a technology transfer from Gilead, enabling the company to manufacture low-cost versions of Tenofovir Alafenamide (TAF), if approved as a single agent or in approved combinations containing Tenofovir Alafenamide (TAF) for developing markets. Phase III trials by Gilead Sciences met their primary objective supporting the potential for Tenofovir Alafenamide (TAF) to provide a new treatment option for individuals living with HIV.
    [Show full text]
  • Johnson & Johnson Has Made a New Breakthrough In
    Investment idea: “Johnson & Johnson has made a new breakthrough in medicine! Shares are growing!” Johnson & Johnson (#JNJ) – is an American holding company that leads more than 250 subsidiaries worldwide, including: DePuy, Neutrogena, Johnson & Johnson Pharmaceutical Research and Development, Janssen Biotech, Alza, Cilag, Tibotec, Johnson & Johnson Consumer Companies and others. Johnson & Johnson is one of the world’s leading manufacturers of medical equipment, medicines and sanitary products. The total revenue of the company for 2018 amounted to $ 81.39 billion. Johnson & Johnson was founded in 1886. Factors indicating the purchase of JNJ shares in December: 1. Breakthrough developments in oncology. Johnson & Johnson is one of the leading companies in the field of oncology. So, the company Johnson & Johnson in November received positive reviews about the trials of a new drug from one of the kinds of cancer. It was immediately called a breakthrough. So far there is little news about this drug, but Johnson & Johnson shares are already strengthening on these information. 2. Seasonality and ascending dynamics of the DOW 30 index. Johnson & Johnson shares are prone to seasonal fluctuations, especially on the eve of the Christmas and New Year holidays. Cosmetology products and hygiene products of Johnson & Johnson are a classic gift in this period. The DOW 30 index, which includes JNJ shares, forms a reversal after a decline, which indicates a fundamental support. It is worth noting that the shares of Johnson & Johnson did not change significantly during the general decline in the stock index DOW 30. Fig. 1. DOW 30 index chart (blue line is JNJ shares) Johnson & Johnson shares are more likely to rise, despite the decline in the DOW30 index.
    [Show full text]
  • In the Supreme Court of the United States   ACORDA THERAPEUTICS, INC., Petitioner
    NO. 181280 In the Supreme Court of the United States ACORDA THERAPEUTICS, INC., Petitioner, v. ROXANE LABORATORIES, INC., MYLAN PHARMACEUTICALS, INC., and TEVA PHARMACEUTICALS USA, INC., Respondents. On Petition for a Writ of Certiorari to the United States Court of Appeals for the Federal Circuit BRIEF OF AMICUS CURIAE BOSTON PATENT LAW ASSOCIATION IN SUPPORT OF NEITHER PARTY SOPHIE F. WANG COUNSEL OF RECORD BRYANA T. MCGILLYCUDDY NATALIA SMYCHKOVICH CHOATE HALL & STEWART LLP TWO INTERNATIONAL PLACE BOSTON, MA 02110 (617) 248-5000 [email protected] MAY 8, 2019 COUNSEL FOR AMICUS CURIAE SUPREME COURT PRESS ʕ (888) 958-5705 ʕ BOSTON, MASSACHUSETTS i TABLE OF CONTENTS Page TABLE OF AUTHORITIES ....................................... ii INTEREST OF THE AMICUS CURIAE ................... 1 SUMMARY OF ARGUMENT .................................... 1 ARGUMENT ............................................................... 3 I. THE FEDERAL CIRCUIT’S DECISION CREATES SIGNIFICANT UNCERTAINTY CONCERNING THE SCOPE AND APPLICABILITY OF THE BLOCKING PATENT DOCTRINE. ............................................ 3 A. Clarification Is Needed as to the Definition of a “Blocking Patent.” .............. 3 B. Clarification Is Also Needed as to Whether and How the Blocking Patent Doctrine Should Be Applied to Objective Indicia of NonObviousness. ...................... 8 II. ABSENT CLARIFICATION, THE EXPANDED BLOCKING PATENT DOCTRINE HAS A CHILLING EFFECT ON INNOVATION AND INVESTMENT. .................. 11 A. Improvement Innovations Are Critical and Require Significant Investment. ....... 11 B. Objective Indicia Matter. .......................... 13 CONCLUSION .......................................................... 16 ii TABLE OF AUTHORITIES TABLE OF AUTHORITIES Page CASES Acorda Therapeutics, Inc. v. Roxane Labs., Inc., 903 F.3d 1310 (Fed. Cir. 2018) ......... passim Apple v. ITC, 725 F.3d 1356 (Fed. Cir. 2013) ......................... 14 Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661 (1990) ............................................. 6 Galderma Labs., L.P.
    [Show full text]
  • Approved Prenatal Medications Pain Medications • Tylenol
    Approved Prenatal Medications Pain Medications Tylenol (acetaminophen) for minor aches and pains, headaches. (Do not use: Aspirin, Motrin, Advil, Aleve, Ibuprofen.) Coughs/Colds Robitussin (Cough) Robitussin DM (non-productive cough) DO NOT USE TILL OVER 12 WEEKS Secrets and Vicks Throat Lozenges Mucinex Sore Throat Chloraseptic spray Saline Gargle Sucrets and Vicks Throat Lozenges Antihistamines/Allergies Zyrtec Claritin Benadryl Dimetapp Insomnia Benadryl Unison Hemorrhoids Preparation H Tucks Anusol Diarrhea Imodium (1-2 doses- if it persists please notify the office) BRAT diet (bananas, rice, applesauce, toast) Lice RID (only!) DO NOT USE Kwell Itching Benadryl Calamine or Caladryl Lotion Hydrocortisone cream Heartburn, Indigestion, Gas Tums Gas-X Mylanta Pepcid Maalox Zantac *DO NOT USE PEPTO BISMOL- it contains aspirin Decongestants Sudafed Robitussin CF- Only if over 12 weeks Tavist D Ocean Mist Nasal Spray (saline solutions) Nausea Small Frequent Meals Ginger Ale Vitamin B6 Sea Bands Yeast Infections Monistat Mycolog Gyne-lotrimin Toothache Orajel May see dentists, have cavity filled using Novocain or lidocaine, have x-rays with double lead shield, may have antibiotics in the Penicillin family (penicillin, amoxicillin) Sweetners- all should be consumed in moderation with water being consumed more frequently Nutrisweet (aspartame) Equal (aspartame) Splenda (sucralose) Sweet’n Low (saccharin) *note avoid aspartame if you have phenylketonuria (PKU) Constipation Colace Fibercon Citrucel Senokot Metamucil Milk of Magnesia Fiberall Miralax Eczema Hydrocortisone Cream Medications to AVOID Accurate Lithium Paxil Ciprofloxacin Tetracycline Coumadin Other Chemicals to AVOID Cigarettes Alcohol Recreational Drugs: marijuana, cocaine, ecstasy, heroin .
    [Show full text]
  • Merck & Co., Inc
    As filed with the Securities and Exchange Commission on February 25, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 _________________________________ FORM 10-K (MARK ONE) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2020 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 1-6571 _________________________________ Merck & Co., Inc. 2000 Galloping Hill Road Kenilworth New Jersey 07033 (908) 740-4000 New Jersey 22-1918501 (State or other jurisdiction of incorporation) (I.R.S Employer Identification No.) Securities Registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on which Registered Common Stock ($0.50 par value) MRK New York Stock Exchange 1.125% Notes due 2021 MRK/21 New York Stock Exchange 0.500% Notes due 2024 MRK 24 New York Stock Exchange 1.875% Notes due 2026 MRK/26 New York Stock Exchange 2.500% Notes due 2034 MRK/34 New York Stock Exchange 1.375% Notes due 2036 MRK 36A New York Stock Exchange Number of shares of Common Stock ($0.50 par value) outstanding as of January 31, 2021: 2,530,315,668. Aggregate market value of Common Stock ($0.50 par value) held by non-affiliates on June 30, 2020 based on closing price on June 30, 2020: $195,461,000,000. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]